

# Hepatobiliary and Pancreas Disease-Oriented Team

---

Clinical Research Treatment Trial Flowchart

LOCOREGIONAL	FIRST LINE	SECOND LINE	THIRD LINE
<p><b><u>UCI 20-84/Instylla</u></b> Hydrogel embolic system vs SOC TAE/cTACE</p> <p>Coord: M. Duron Accrual: 8/13</p>	<p><b><u>UCI 22-106</u></b> STAT3 ± Pembrolizumab or ± Atezolizumab and Bevacizumab</p> <p>Coord: H. Nguyen Accrual: 5/10</p>		
<p><b><u>UCI 19-49</u></b> Cabo + Ipi/Nivo + TACE</p> <p>Coord: H. Nguyen Accrual: 15/35</p>	<p><b><u>UCI 23-91</u></b> INCB099280 (Oral PDL1) + Ipilimumab anti-PDL1/anti-CTLA4 naïve</p> <p>Coord: C. Kang Accrual: 0/15</p>		
<p><b><u>UCI 23-75/ROUTE 90</u></b> Eye90 microspheres</p> <p>Coord: M. Duron Accrual: 0/15</p>	<p><b><u>UCI 22-211</u></b> MED1572 (IgG1 mAb) ± Bev ± Lenvatinib Slot request required Coord: C. Kang Accrual: 2/8</p>	<p><b><u>UCI 23-58</u></b> Livmoniplimab + Budigalimab or Lenvatinib or Sorafenib * Must never have received a TKI Coord: H. Nguyen Accrual: 0/10</p>	
	<p><b><u>UCI 23-104</u></b> Livmoniplimab + Budigalimab Atezolizumab + Bevacizumab Tremelimumab + Durvalumab</p> <p>Coord: H. Nguyen Accrual: 0/7</p>	<p><b><u>UCI 16-94</u></b> TATE + Nivolumab (includes gastric/GEJ)</p> <p>Coord: M. Duron Accrual: 24/40</p>	
	<p><b><u>UCI 23-86</u></b> Atezolizumab ± Bevacizumab (Child-Pugh B7 and B8)</p> <p>Coord: M. Duron Accrual: 0/10</p>	<p><b><u>UCI 23-24</u></b> HAI SD-101 + Pembrolizumab or Nivolumab</p> <p>Budget pending</p>	

## RESECTABLE

### EA2197/OPT-IN

Gemcitabine + Cisplatin: Neo  
+ Adjuvant or Adjuvant only  
Incidental gallbladder

Coord: J. Balanguie  
Accrual: 0/10

## FIRST LINE

### UCI 22-212

(includes Ampullary)

Durvalumab + any  
gemcitabine-based regimen

Coord: N. Ferrand  
Accrual: 2/8

### UCI 22-211

MED1572 (IgG1 mAb) or  
AZD2936 (TIGIT) ±  
gemcitabine and cisplatin

Slot request required

Coord: C. Kang  
Accrual: 2/8

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

## SECOND LINE+

### ETCTN-10276

M3814 ± Avelumab +  
Hypofraction Radiation

Coord: N. Ferrand  
Accrual: 1/5

## SECOND LINE+ (INTRAHEPATIC)

### UCI 23-24

HAI SD-101 + Pembro or Nivo

Budget pending

**PERIOPERATIVE**

**A021806**  
 Neo/adjuvant vs adjuvant  
 mFOLFIRINOX

Coord: J. Balague  
 Accrual: 0/15

**UCI 22-75**  
 ELI-002 7P (oncolytic virus)  
 (KRAS Local testing)  
 Within 6 months of resection  
 or last adjuvant treatment

Coord: M. Duron  
 Accrual: 1/7

**BORDERLINE/LOCALLY ADVANCED**

**ETCTN-10366**  
 M3814 (Peposertib) + radiation  
 therapy

Coord: H. Nguyen  
 Accrual: 4/8

**ETCTN-10464**  
 Olaparib with Durvalumab +  
 radiation therapy

Coord: H. Nguyen  
 Accrual: 0/5  
 Suspended for analysis

**FIRST LINE METASTATIC**

**S2001**  
 Olaparib +/- Pembrolizumab  
 (BRCA 1/2, STABLE DISEASE)

Coord: J. Balague  
 Accrual: 2/4

**SECOND LINE**

**ETCTN 10522**  
 CA4948 + gemcitabine + nab-  
 paclitaxel

Coord: H. Nguyen  
 Accrual: 3/4

**A022106**  
 Nab-paclitaxel + Gemcitabine  
 ± Cisplatin  
*BRCA1/2 or PALB2*  
*PD on 1L FOLFIRINOX*

Coord: J. Balague  
 Accrual: 0/3

**RECURRENT METASTATIC**

**Review Biomarker Based  
 Solid Tumors Pages 6 and 7**

**ADJUVANT**

S2104

Capecitabine + Temozolomide  
vs observation

Pancreatic NET Ki67 > 3%

Coord: J. Balangue  
Accrual: 0/2

Mutation based studies allowing Pancreatic, HCC, and Biliary cancers + other solid tumors

■ Open to Accrual

■ Low Accruing

■ Pending Activation/Suspended

## HER2

### UCI 20-67

DF1001 +/- nivo

Coord: M. Nguyen  
Accrual: 18/20

### UCI 21-57

ALX148 + Zanidatamab

Coord: A. Chavez  
Accrual: 4/5

### UCI 23-66

BI 1810631 (HER2 Inhibitor)

Coord: C. Smith  
Accrual: 0/5

## TISSUE FACTOR

### UCI 21-146

MRG004A (TF ADC)

Coord: M. Duron  
Accrual: 4/11

## KRAS/NRAS

### UCI 21-53

LY3537982 (KRAS G12C Inhibitor)

Coord: J. Choe  
Accrual: 6/8

### 22-87

RMC-6236 (KRAS Inhibitor)

Pancreatic KRAS G12 and other RAS-type

Coord: C. Kang  
Accrual: 11/20

## INHERITED MUTATIONS

### ETCTN-10528

Novobiocin (POLθ)

Coord: H. Nguyen  
FDA hold

## EGFR

### UCI 22-171

EGFR TriNKET +/- Nivolumab (Central testing)

Coord: M. Nguyen  
Accrual: 3/15

Mutation based studies allowing Pancreatic, HCC, and Biliary cancers + other solid tumors

■ Open to Accrual

■ Low Accruing

■ Pending Activation/Suspended

## CLAUDIN 18.2

**UCI 22-51**  
ASP2138 (CLDN18.2)

Pancreatic and  
Gastric/GEJ

Coord: L. Mejia  
Accrual: 0/10

## EpCAM

**UCI 23-85**  
BA3182 (CAB T-cell:  
EpCAM)

All solid tumors (central  
EPCAM testing)

IRB, budget, CTA  
pending

## B7-H6

**UCI 22-221**  
BiTe of B7-H6

(Central B7-H6 testing)  
HCC and Pancreatic  
(also NSCLC, HNSCC,  
CRC, and gastric)

Coord: P. Yang  
Accrual: 2/12

Various solid tumors included, or have progressed on, exhausted all therapies, or not amenable to further treatment

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

### UCI 22-26

CB-03-10 (Androgen and glucocorticoid antagonist)

All solid tumors

Coord: N. Ferrand  
Accrual: 7/12

### UCI 23-07

P-MUC1C-ALLO1 (CAR-T Cell)

RR1 sign off

### UCI 22-37

TACH101 (KDM4C inhibitor)

Phase 1: all solid tumors

Coord: A. Luna  
Accrual: 4/10

### UCI 23-91

INCB099280 (Oral CPI) + Ipilimumab

**Phase 1:** HCC, ccRCC, Melanoma, MSI-H/dMMR Colorectal  
**Expansion:** HCC, ccRCC

Must be anti-PDL1 or anti-CTLA-4 naive

Pending Site Initiation



## BLOOD COLLECTION

### UCI 21-124

ctDNA collection during HBP workup

Coord: J. Balanguie  
Accrual: 12/15

### UCI 23-10/PRECEDE

(Blood collection for early detection of pancreatic cancer)

Pending budget/contract

### UCI 20-101

(Biospecimen Collection for patients planned to start IO treatment)

Coord: J. Koff  
Accrual: 53/80

## SUPPORTIVE

### UCI 22-109

Palonosetron IV vs. Buccal film anti-emetic

Coord: P. Yang  
Accrual: 1/30

■ Open to Accrual   ■ Low Accruing   ■ Pending Activation/Suspended